Literature DB >> 25410169

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.

Ozdemir Ozdemir1, Ozgul Altintas2, Levent Altintas3, Berna Ozkan2, Cigdem Akdag2, Nurşen Yüksel2.   

Abstract

PURPOSE: To compare the effects of bevacizumab applied either subconjunctivally or topically, in a rat model of corneal neovascularization induced by alkali burn.
METHODS: The right corneas of 24 Wistar-Albino rats were cauterized with silver nitrate sticks. The rats were divided randomly and equally into three groups: no treatment control (n=8), subconjunctival bevacizumab treatment (n=8), and topical bevacizumab treatment (n=8). Immediately following cauterization, the subconjunctival group was treated with a 0.05 ml (1.25 mg) bevacizumab subconjunctival injection. The topical group was treated with 10 mg/ml bevacizumab twice daily, and the control group received subconjunctival saline injections twice daily. The burn stimulus and neovascularization scores were evaluated using a technique previously described by Mahoney and Waterbury. Digital photographs were obtained before the eyes were enucleated and corneal sections were then analyzed by histopathology.
RESULTS: The mean burn stimulus score was 1.86 ± 0.6 and there was no statistical difference between the groups (p=0.730). The mean neovascularization scores in the subconjunctival and topical bevacizumab groups were statistically lower than the control group (p<0.05). The mean percentage area of corneal neovascularization was 82.5 ± 22.1 in the control group, 42.7 ± 15.0 in the subconjunctival group, and 55.8 ± 18.2 in the topical group. The differences between the control and treatment groups were statistically significant (p<0.05). Histopathology showed that the treatment groups presented less neovascularization, inflammation, and fibroblast activity than the control group (p<0.05).
CONCLUSIONS: This study demonstrates that both subconjunctival and topical administrations of bevacizumab inhibit corneal neovascularization and decrease inflammation and fibroblast activity in a rat model of corneal neovascularization induced by alkali burn.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25410169     DOI: 10.5935/0004-2749.20140054

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  10 in total

1.  Inhibitory Effect of Topical Cartilage Acellular Matrix Suspension Treatment on Neovascularization in a Rabbit Corneal Model.

Authors:  Hee-Woong Yun; Byung Hyune Choi; Do Young Park; Long Hao Jin; Byoung-Hyun Min
Journal:  Tissue Eng Regen Med       Date:  2020-07-02       Impact factor: 4.169

2.  Intrastromal versus subconjunctival anti-VEGF agents for treatment of corneal neovascularization: a rabbit study.

Authors:  Rukiye Kilic Ucgul; Serdal Celebi; Niyazi Samet Yilmaz; Neslihan Bukan; Ahmet Yucel Ucgul
Journal:  Eye (Lond)       Date:  2021-01-19       Impact factor: 3.775

Review 3.  The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review).

Authors:  Hongyan Zhou; Wensong Zhang; Miaomiao Bi; Jie Wu
Journal:  Int J Mol Med       Date:  2016-08-04       Impact factor: 4.101

4.  The inhibitory effect of different concentrations of KH902 eye drops on corneal neovascularization induced by alkali burn.

Authors:  Yan Wu; Chunyan Xue; Yan Lu; Zhenping Huang
Journal:  Indian J Ophthalmol       Date:  2017-11       Impact factor: 1.848

Review 5.  Therapeutic approaches for corneal neovascularization.

Authors:  Sepehr Feizi; Amir A Azari; Sharareh Safapour
Journal:  Eye Vis (Lond)       Date:  2017-12-10

Review 6.  Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.

Authors:  Tariq Al-Debasi; Abdulkareem Al-Bekairy; Abdulmalik Al-Katheri; Shmeylan Al Harbi; Mahmoud Mansour
Journal:  Saudi J Ophthalmol       Date:  2017-03-08

7.  Subconjunctival bevacizumab and argon laser photocoagulation for preexisting neovascularization following deep lamellar anterior keratoplasty.

Authors:  Meena Lakshmipathy; Pradeep Susvar; Kshama Popet; Rama Rajagopal
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

8.  Serum vascular endothelial growth factor changes and safety after topical anti-human VEGF antibody bevacizumab in healthy dogs.

Authors:  Lisa-Marie Muellerleile; Alexander Tichy; Barbara Nell
Journal:  Vet Ophthalmol       Date:  2019-02-04       Impact factor: 1.644

9.  Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera.

Authors:  Steven A Giannos; Edward R Kraft; Zhen-Yang Zhao; Kevin H Merkley; Jiyang Cai
Journal:  Pharm Res       Date:  2018-03-29       Impact factor: 4.200

Review 10.  Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.

Authors:  Zachary Barry; Bomina Park; Timothy W Corson
Journal:  Molecules       Date:  2020-07-30       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.